



IDS/#1
J894 Rec'd PCT/PTO 29 JUN 2001
18/02

Attorney Docket: ISC.007/PCT-US

TECH CENTER 1600/2900

JAN 07 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: BAR-OR *ET AL.*)
SERIAL NO.: 09/806,247) EXAMINER:
FILED: OCTOBER 1, 1999) ART UNIT:
TITLE: TEST FOR THE RAPID)
EVALUATION OF ISCHEMIC)
STATES AND KIT)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above-identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.


37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231 on June 27, 2001

Signature:
Name:

Cindy Bennett



No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Supplemental Information Disclosure Statement shall not be construed as an admission against interest in any manner. The listed patents and publications are believed of interest herein and consideration and citation as of interest by Examiner is respectfully requested.

Respectfully submitted,

Margaret M. Wall

Margaret M. Wall, #33,462
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
Telephone: (303) 268-0066

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number	09/806,247
Filing Date	October 1, 1999
First Named Inventor	Bar-Or et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ISC.004/PCT-US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	3,955,926		Fischer	05/11/76	
	AB	4,379,848		Yeaw	04/12/83	
	AC	4,434,234		Adams et al.	02/28/84	
	AD	4,468,466		Morrissey	08/28/84	
	AE	4,486,282		Bier	12/04/84	
	AF	4,492,753		Shell et al.	01/08/85	
	AG	4,713,327		Findlay et al.	12/15/87	
	AH	4,786,605		Mauck et al.	11/22/88	
	AI	5,227,307		Bar-Or et al.	07/13/93	
	AJ	5,290,519		Bar-Or et al.	03/01/94	
	AK	5,503,987		Wagner et al.	04/02/96	
	AL	5,604,105		Jackowski	02/18/97	
	AM	5,639,624		Wagner et al.	06/17/97	
	AN	5,683,907		Johnson	11/04/97	
	AO	5,710,008		Jackowski	01/20/98	
	AP	6,083,758		Imperiali et al.	07/04/00	
	AQ	09/165,961		Bar-Or et al.	10/02/98	
	AR					
	AS					
	AT					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AU		WO 00/20454		PCT	04/13/00		
	AV							
	AW							
	AX							
	AY							
	AZ							
	BA							
	BB							
	BC							
	BD							

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Completion if Known

Application Number	09/806,247
Filing Date	October 1, 1999
First Named Inventor	Bar-Or et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ISC.004/PCT-US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Fleming and Nixon, A Versatile Transition Metal Salt Reaction for a Wide Range of Common Biochemical Reagents; An Instantaneous and Quantifiable Color Test, Analytical Biochemistry 154(2):691-701 (1986)	
		Yoon et al. (1989) The Role of Metal Ions in Ischemia/Reperfusion Injury in Skin Flaps, Journal of Surgical Research, 46:163-165	
		Karck et al. (1992) TPEN, A Transition Metal Chelator, Improves Myocardial Protection During Prolonged Ischemia, The Journal of Heart and Lung Transplantation, 11:979-985	
		Laussac and Sarkar (1984) Characterization of The Copper(II)-Transport Site of Human Serum Albumin. Studies of Copper(II) and Nickel(II) Binding to Peptide 1-24 of Human Serum Albumin by ¹³ C and ¹ H NMR Spectroscopy, Biochemistry 23:2832-2838	
		Cotelle et al. (1992) Redox Chemistry of Complexes of Nickel (II) with some Biologically Important Peptides in the Presence of Reduced Oxygen Species: An ESR Study, J. Inorganic Biochemistry 46:7-15	
		Keller et al. (1993) Immunochemical Detection of Oxidized Proteins, Chem. Res. Toxicol. 6:430-433	
		Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 6, pp. 139-243.	
		Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 14, pp. 553-612.	
		Chan et al. (1995) Site-Specific N-Terminal Auto-Degradation of Human Serum Albumin, Eur. J. Biochem. 227:524-528	
		Anderson et al (1995) Effects of Na ⁺ K ⁺ -2Cl ⁻ Cotransport Inhibition on Myocardial NA and CA During Ischemia and Reperfusion, found at http://www.uth.tmc.edu/apstracts/1995/cell/september 319c.html , p.1, published in APSTRACTS on September 23, 1995	
		Davies (1986) Intracellular Proteolytic Systems May Function as Secondary Antioxidant Defenses: An Hypothesis, Journal of Free Radicals in Biology & Medicine 2:155-161 and pp. 164-169	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **3** of **8**

C mplet if Kn wn

Application Number	09/806,247
Filing Date	October 1, 1999
First Named Inventor	Bar-Or et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ISC.004/PCT-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Gomez et al (1996) Ruling Out Ischemia Saves Time and Money, Clinician Reviews 6:148 or J. Am. Coll. Cardiol. 28:25-33	
		Halliwell (1988) Albumin – An Important Extracellular Antioxidant?, Biochemical Pharmacology 37:569-571	
		Halliwell and Gutteridge (1990) The Antioxidants of Human Extracellular Fluids, Archives of Biochemistry and Biophysics 280:1-8	
		Halliwell and Gutteridge (1986) Oxygen Free Radicals and Iron in Relation to Biology and Medicine: Some Problems and Concepts, Archives of Biochemistry and Biophysics 246:501-514	
		Hayakawa et al. (1997) Alteration of Redox State of Human Serum Albumin in Patients Under Anesthesia and Invasive Surgery, Journal of Chromatography 698:27-33	
		Huang et al. (1995) Ischemia- and Reperfusion-Sensitive Cardiac Sympathetic Afferents: Influence of Hydrogen Peroxide and Hydroxyl Radicals, Abstract 2:0120H found at http://www.uth.tmc.edu/apstracts;1995/heart/April/120h.html	
		Marx and Chevion (1985) Site-Specific Modification of Albumin by Free Radicals, Biochem. J. 236:397-400	
		QLT Phototherapeutics, Inc., Product Brochure: Photofrin, Manufactured by Lederly Parenterals, Inc. (April 1996)	
		Predki et al. (1992) Further Characterization of the N-Terminal Copper(II)- and Nickel(II)- Binding Motif of Proteins, Biochem. J. 287:211-215	
		New Marker for Exercise-Induced Ischemia, Diagnostic Profile, May 1997, Clinical Laboratory News found at http://www.aacc.org/cln/profiles/97profiles/05/diagpro9702.html	
		Sheat et al. (1991) Rapid Detection and Initial Characterization of Genetic Variants of Human Serum Albumin, Clin. Chem. 37:1221-1224	

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+ TECH CENTER 1600/2000 JAN 07 2002

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **4** of **8**

Complete if Known

Application Number	09/806.247
Filing Date	October 1, 1999
First Named Inventor	Bar-Or et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ISC.004/PCT-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Sogami et al. (1984) Resolution of Human Mercapt- and Nonmercaptalbumin by High-Performance Liquid Chromatography, Int. J. Peptide Protein Res. 24:96-103	
		Wysocki et al. (1993) Peroxide Plasma Level in Patients with Coronary Heart Disease as a Possible Indicator of Ischemia During Exercise Test, Coronary Artery Disease 4:645-647	
		Bautista and Mateos-Nevado (1998) Immunological Detection and Quantification of Oxidized Proteins by Labelling with Digoxigenin, Biosci. Biotechnol. Biochem. 62:419-423	
		Das and Maulik (1994) Antioxidant Effectiveness in Ischemia-Reperfusion Tissue Injury, Methods in Enzymology 233:601-611	
		Davies and Delsignore (1987) Protein Damage and Degradation by Oxygen Radicals, J. Biological Chemistry, 262:9908-9913	
		Gutteridge and Wilkins (1983) Copper Salt-Dependent Hydroxyl Radical Formation Damage to Proteins Acting as Antioxidants, Biochimica et Biophysica Acta 759:38-41	
		Quinlan et al. (1992) Vanadium and Copper in Clinical Solutions of Albumin and Their Potential to Damage Protein Structure, J. Pharmaceutical Sciences 81:611-614	
		Röth (1997) Oxygen Free Radicals and Their Clinical Implications, Acta Chirurgica Hungarica 35:302-305	
		Stohs (1995) The Role of Free Radicals in Toxicity and Disease, J. Basic and Clinical Physiology and Pharmacology 6:205-228	
		Sadler et al. (1994) Involvement of a Lysine Residue in the N-Termial Ni ²⁺ and Cu ²⁺ Binding Site of Serum Albumins. Comparison with Co ²⁺ , Cd ²⁺ and Al ³⁺ , Abstract found at http://search19.proxy.aol.com:8000/post-query/MedLine/hrs1994/23450? albumin+n+terminal or Eur. J. Biochem. (1994) 220:193-200	
		Ueda et al. (1995) Reactions of Copper(II)-Oligopeptide Complexes with Hydrogen Peroxide: Effects of Biological Reductants, Free Radical Biology & Medicine 18:929-933	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 8

Complete if Known

Application Number	09/806,247
Filing Date	October 1, 1999
First Named Inventor	Bar-Or et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ISC.004/PCT-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Afanas'ev, Superoxide Ion: Chemistry and Biological Implications, Volume II, Oxygen Radicals in Biology, CRC Press, pp. 138 and 187	
		Boehringer Mannheim Catalog No. 15947 for 30 - 80 tests, page 375	
		Dolovich et al. (1984) Occupational Asthma from Nickel Sensitivity: I Human Serum Albumin in the Antigenic Determinant, British Journal of Industrial Medicine 41:51-55	
		Genest, Jr. et al., Plasma Homocyst(3)ine Levels in Men With Premature Coronary Artery Disease, JACC 16 :1114-1119 (1990)	
		Glutathione, Interconversion of Glutathione and Glutathione Disulfide, pp. 733-739	
		Magano et al., Associate of Perioperative Myocardial Ischemia with Cardiac Morbidity and Mortality in Men Undergoing Noncardiac Surgery, The New England Journal of Medicine, 323:1781-1788 (1990)	
		Metal-Binding Groups of Proteins. Chapter IV, A. Evidence for Specific Donor Atoms, pp. 61-99	
		Nieboer et al. (1984), Occupation Asthma from Nickel Sensitivity: II Factors Influencing the Interaction of Ni ²⁺ , HSA, and Serum Antibodies with Nickel Related Specificity, British Journal of Industrial Medicine 41:56-63	
		Odea (1991), The Role of Reperfusion-Induced Injury in the Pathogenesis of the Crush Syndrome, Mechanisms of Disease 324:1417-1422	
		Shirakawa et al. (1992) Specific IgE Antibodies to Nickel in Workers with Known Reactivity to Cobalt, Clinical and Experimental Allergy 22:213-218	
		Shirakawa et al. (1990) Hard Metal Asthma: Cross Immunological and Respiratory Reactivity Between Cobalt and Nickel, Thorax 45:267-271	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

Complete if Known

Application Number	09/806,247
Filing Date	October 1, 1999
First Named Inventor	Bar-Or et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ISC.004/PCT-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Shirakawa et al. (1988) The Existence of Specific Antibodies to Cobalt in Hard Metal Asthma, Clinical Allergy 18:451-460	
		Toxicity and Physicochemical Properties of Metal, Coordination and Chelation, Chapter 4, pp. 115-122	
		Veien et al. (1979), Antibodies Against Nickel-Albumin in Rabbits and Man, Contact Dermatitis, 5:378-382	
		Venugopal and Luckey, Metal Toxicity in Mammals - 2, Chemical Toxicity of Metals and Metalloids, Plenum Press, pp. 282-289	
		Witko-Sarsat et al. (1996) Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in Uremia, Kidney International 49:1304-1313	
		Cobbe and Poole-Wilson (1980) The Time of Onset and Severity of Acidosis in Myocardial Ischaemia, Journal of Molecular and Cellular Cardiology 12:745-760	
		Reimer et al. (1977) the Wavefront Phenomenon of Ischemic Cell Death, 1. Myocardial Infarct Size vs. Duration of Coronary Occlusion in Dogs, Circulation 56:786-794	
		Reimer and Jennings (1992) Myocardial Ischemia, Hypoxia and Infarction, The Heart and Cardiovascular System, Second Edition, Chapter 75, pp. 1875-1951, H.A. Fozzard et al., ed. Raven Press, Ltd., New York	
		Ishikawa et al (1997) Reversible Myocardial Ischemic Injury is not Associate with Increased Creatine Kinase Activity in Plasma, Clinical Chemistry 43:467-475	
		Roberts (1997) Rapid MB CK Subform Assay and the Early Diagnosis of Myocardial Infarction, Clinics in Laboratory Medicine 17:669-683	
		Göbel et al (1998) Long-term Follow-up after Early Intervention with Intravenous Diltiazem or Intravenous Nitroglycerin for Unstable Angina Pectoris, European Heart Journal 19:1208-1213	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 8

Compleat if Kn wn

Application Number	09/806,247
Filing Date	October 1, 1999
First Named Inventor	Bar-Or et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ISC.004/PCT-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Pepine et al. (1994) Effects of Treatment on Outcome in Mildly Symptomatic Patients with Ischemia During Daily Life, Circulation 90:762-768	
		Hedges et al. (1996) Prospective Assessment of Presenting Serum Markers for Cardiac Rsk Stratification, Acad. Emerge. Med. 3:27-33	
		Masuoka et al. (1993) Intrinsic Stoichiometric Equilibrium Constants for the Binding of Zinc(II) and Copper(II) to the High Affinity Site of Serum Albumin, The Journal of Biological Chemistry 268:21533-21537	
		McCord (1985) Oxygen-Derived Free Radicals in Postischemic Tissue Injury, The New England Journal of Medicine 312:159-163	
		Kadota et al. 1990) Decreased Sulfhydryl Groups of Serum Albumin in Coronary Artery Disease, Japanese Circulation Journal 55:937-941	
		Braugher (1987) Calcium and Lipid Peroxidation, from Central Nervous System Diseases Research Unit, p. 99, The Upjohn Company, Kalamazoo, Michigan	
		Davies (1987) Protein Damage and Degradation by Oxygen Radicals, I., General Aspects, The Journal of Biological Chemistry 262:9895-9901	
		Halliwell (1987) Oxygen Radicals and Tissue Injury, Proceedings of a Brook Lodge Symposium, August, Michigan, April 27-29, 1987	
		DNA Damage Linked to Risk of Breast Cancer Spread, found at http://www.pslgroup.com/dg/6c2d.htm (1996)	
		Davies and Goldberg (1987) Oxygen Radicals Stimulate Intracellular Proteolysis and Lipid Peroxidation by Independent Mechanisms in Erythrocytes, The Journal of Biological Chemistry 262:8220-8226	
		Ishimoto et al. (1996) Role of Oxygen-Derived Free Radicals in Fetal Growth Retardation Induced by Ischemia-Reperfusion in Rats, APSTRACTS 3:0371H found at http://oac3.hsc.uth.tmc.edu/apstracts/1996/heart/September/371h.html	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 8

Complete if Known

Application Number	09/806,247
Filing Date	October 1, 1999
First Named Inventor	Bar-Or et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ISC.004/PCT-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Hisashi et al (1997) Atp-Sensitive k ⁺ Channels in Pancreatic, Cardiac, and Vascular Smooth Muscle Cells, APSTRACTS 4:0291C found at http://oac3.hsc.usth.tmc.edu/apstracts/1997/cell/October/291C.html	
		Vogel, Qualitative Chemical Analysis, Reactions of the Metal Ions or Cations, The Zinc Group (Group IIB), pp. 198-202	
		Alberts et al., Molecular Biology of the Cell, Second Edition, Garland Publishing, Inc., (1989), pp. 174-180.	
		Stryer, Biochemistry, Third Edition, W.H. Freeman and Co, (1988), pp.62-64 and 895-897.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.